Interesting study. 79 nr-axSpA pts observed for 6 years. Every 2 yrs approximately 10% of pts progressed from nr-axSpA to AS! Next step: evaluate dz characteristics and determine potential at risk pts. Abs 0907 #ACR21 #RheumNow @RheumNow https://t.co/aRjXWjkVKg https://t.co/BiHFgDR8Kv

• Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients …

Abst0898 #ACR21 @RheumNow MRI findings of Vertebral Corner Inflammation & Vertebral Corner Fat Deposition associated w/syndesmophyte formation 2 y later, ORs 1.87-2.58 for various VCI/VCFD patterns. Protection against syndesmophyte seen if both VCI and VCFD were absent (OR 0.35) https://t.co/t01nxdEwON

There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI

• Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did N…

In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/symptom improvement compared to those w/ late dz. IV GLM better overall regardless of dz duration. Abs 0912 #ACR21 #RheumNow @RheumNow https://t.co/S2L97c7oQO https://t.co/XXpveRwwmQ

• Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients…

Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr

2 year extension study on Upadacitinib in active AS ⭐️ASAS40 response maintained ⭐️MRI SPARCC scores decreased and maintained ⭐️infections most common AE ⭐️NO MACE, lymphoma, skin cancer, GI perforations Abs#924 #ACR21 #ACRBest @RheumNow https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ

• Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…

No significant difference in effectiveness/treatment survival of different TNFi in axSpA Failure of 1st TNFi did not diminish effectiveness of a second TNFi Abs#938 #ACR21 @RheumNow https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6

• Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors fo…

Abst 0947 #ACR21 @RheumNow KikGR x TNFDARE/+ mice study assessed contribution of gut-derived T cells to increased joint inflammation through production of pro-inflammatory cytokines like IL-17 and TNF. Photolabeled gut-trafficked T cells are observed in the Achilles enthesis